
Dennis Bruemmer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4663092/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Remnant Cholesterol. Circulation: Cardiovascular Imaging, 2021, 14, e012615.	2.6	7
2	Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities. Cardiovascular Endocrinology and Metabolism, 2020, 9, 81-89.	1.1	14
3	Telomerase Deficiency Predisposes to Heart Failure and Ischemia-Reperfusion Injury. Frontiers in Cardiovascular Medicine, 2019, 6, 31.	2.4	26
4	Mechanisms of Trained Innate Immunity in oxLDL Primed Human Coronary Smooth Muscle Cells. Frontiers in Immunology, 2019, 10, 13.	4.8	56
5	Confirmatory Tests for the Diagnosis of Primary Aldosteronism. Hypertension, 2018, 71, 118-124.	2.7	84
6	Telomerase Reverse Transcriptase Deficiency Prevents Neointima Formation Through Chromatin Silencing of E2F1 Target Genes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 301-311.	2.4	14
7	Deletion of the NR4A nuclear receptor NOR1 in hematopoietic stem cells reduces inflammation but not abdominal aortic aneurysm formation. BMC Cardiovascular Disorders, 2017, 17, 271.	1.7	12
8	Differential Regulation of Telomerase Reverse Transcriptase Promoter Activation and Protein Degradation by Histone Deacetylase Inhibition. Journal of Cellular Physiology, 2016, 231, 1276-1282.	4.1	12
9	Vascular smooth muscle cell dysfunction in diabetes: nuclear receptors channel to relaxation. Clinical Science, 2016, 130, 1837-1839.	4.3	5
10	Telomerase Inhibition by Everolimus Suppresses Smooth Muscle Cell Proliferation and Neointima Formation Through Epigenetic Gene Silencing. JACC Basic To Translational Science, 2016, 1, 49-60.	4.1	8
11	PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner. Journal of Molecular and Cellular Cardiology, 2015, 81, 23-33.	1.9	29
12	DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle cell proliferation through phosphorylation of the orphan nuclear receptor NOR1. Cardiovascular Research, 2015, 106, 488-497.	3.8	25
13	Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histone acetylation. FEBS Letters, 2014, 588, 4825-4830.	2.8	10
14	Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Molecular Metabolism, 2014, 3, 384-393.	6.5	315
15	Deficiency of the NR4A Orphan Nuclear Receptor NOR1 in Hematopoietic Stem Cells Accelerates Atherosclerosis. Stem Cells, 2014, 32, 2419-2429.	3.2	27
16	Nuclear Receptor 4a3 (Nr4a3) Regulates Murine Mast Cell Responses and Granule Content. PLoS ONE, 2014, 9, e89311.	2.5	17
17	Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans. Science Translational Medicine, 2013, 5, 209ra151.	12.4	461
18	Activation of Liver X Receptor Inhibits Osteopontin and Ameliorates Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1835-1846.	6.1	49

DENNIS BRUEMMER

#	Article	IF	CITATIONS
19	Transient Exposure of Neonatal Female Mice to Testosterone Abrogates the Sexual Dimorphism of Abdominal Aortic Aneurysms. Circulation Research, 2012, 110, e73-85.	4.5	60
20	Regulation of Peroxisome Proliferator–Activated Receptor-γ by Angiotensin II Via Transforming Growth Factor-β1–Activated p38 Mitogen-Activated Protein Kinase in Aortic Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 397-405.	2.4	30
21	Targeting Angiogenesis as Treatment for Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 161-162.	2.4	10
22	Novel Mechanisms of Abdominal Aortic Aneurysms. Current Atherosclerosis Reports, 2012, 14, 402-412.	4.8	62
23	Ghrelin receptor deficiency does not affect diet-induced atherosclerosis in low-density lipoprotein receptor-null mice. Frontiers in Endocrinology, 2011, 2, 67.	3.5	8
24	Relevance of angiotensin Ilâ€induced aortic pathologies in mice to human aortic aneurysms. Annals of the New York Academy of Sciences, 2011, 1245, 7-10.	3.8	48
25	Epigenetic Regulation of Vascular Smooth Muscle Cell Proliferation and Neointima Formation by Histone Deacetylase Inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 851-860.	2.4	117
26	Telomerase Activation in Atherosclerosis and Induction of Telomerase Reverse Transcriptase Expression by Inflammatory Stimuli in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 245-252.	2.4	80
27	Telomerase Deficiency in Bone Marrow–Derived Cells Attenuates Angiotensin II–Induced Abdominal Aortic Aneurysm Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 253-260.	2.4	20
28	Transcriptional Regulation of S Phase Kinase-associated Protein 2 by NR4A Orphan Nuclear Receptor NOR1 in Vascular Smooth Muscle Cells*. Journal of Biological Chemistry, 2011, 286, 35485-35493.	3.4	27
29	Race–ethnicity as an effect modifier of the association between HbAlc and mortality in U.S. adults without diagnosed diabetes. European Journal of Endocrinology, 2011, 165, 275-281.	3.7	11
30	Oxidative Stress Accumulates in Adipose Tissue during Aging and Inhibits Adipogenesis. PLoS ONE, 2011, 6, e18532.	2.5	77
31	Deficiency of telomerase activity aggravates the blood–brain barrier disruption and neuroinflammatory responses in a model of experimental stroke. Journal of Neuroscience Research, 2010, 88, 2859-2868.	2.9	24
32	Pioglitazone-Induced Reductions in Atherosclerosis Occur via Smooth Muscle Cell–Specific Interaction With PPARγ. Circulation Research, 2010, 107, 953-958.	4.5	72
33	Deficiency of the NR4A Orphan Nuclear Receptor NOR1 Decreases Monocyte Adhesion and Atherosclerosis. Circulation Research, 2010, 107, 501-511.	4.5	79
34	NR4A Orphan Nuclear Receptors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1535-1541.	2.4	205
35	Group X Secretory Phospholipase A ₂ Negatively Regulates ABCA1 and ABCG1 Expression and Cholesterol Efflux in Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2014-2021.	2.4	38
36	Intensive glycemic control and cardiovascular disease: an update. Nature Reviews Cardiology, 2010, 7, 369-375.	13.7	149

DENNIS BRUEMMER

#	Article	IF	CITATIONS
37	Deficiency of the NR4A Neuron-Derived Orphan Receptor-1 Attenuates Neointima Formation After Vascular Injury. Circulation, 2009, 119, 577-586.	1.6	73
38	A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nature Chemical Biology, 2009, 5, 749-757.	8.0	512
39	NR4A orphan nuclear receptors in cardiovascular biology. Drug Discovery Today Disease Mechanisms, 2009, 6, e43-e48.	0.8	27
40	Liver X receptors as therapeutic targets in metabolism and atherosclerosis. Current Atherosclerosis Reports, 2008, 10, 88-95.	4.8	33
41	Phosphorylated Troglitazone Activates PPARÎ ³ and Inhibits Vascular Smooth Muscle Cell Proliferation and Proteoglycan Synthesis. Journal of Cardiovascular Pharmacology, 2008, 51, 274-279.	1.9	9
42	The PPARα/p16 ^{INK4a} Pathway Inhibits Vascular Smooth Muscle Cell Proliferation by Repressing Cell Cycle–Dependent Telomerase Activation. Circulation Research, 2008, 103, 1155-1163.	4.5	61
43	PPARÂ Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 Diabetes. Diabetes, 2007, 56, 1662-1670.	0.6	65
44	Zinc Deficiency Alters Lipid Metabolism in LDL Receptor–Deficient Mice Treated with Rosiglitazone. Journal of Nutrition, 2007, 137, 2339-2345.	2.9	32
45	Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice. Journal of Clinical Investigation, 2007, 117, 2877-2888.	8.2	319
46	Osteopontin deficiency protects mice from dextran sodium sulfate-induced colitis. Inflammatory Bowel Diseases, 2006, 12, 790-796.	1.9	40
47	The NR4A Orphan Nuclear Receptor NOR1 Is Induced by Platelet-derived Growth Factor and Mediates Vascular Smooth Muscle Cell Proliferation. Journal of Biological Chemistry, 2006, 281, 33467-33476.	3.4	115
48	Activation of Peroxisome Proliferator-Activated Receptor Î ³ Suppresses Telomerase Activity in Vascular Smooth Muscle Cells. Circulation Research, 2006, 98, e50-9.	4.5	69
49	C-Peptide in Insulin Resistance and Vascular Complications. Circulation Research, 2006, 99, 1149-1151.	4.5	14
50	Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. Journal of Neurochemistry, 2005, 94, 1395-1401.	3.9	42
51	Liver X Receptor Agonists Inhibit Cytokine-Induced Osteopontin Expression in Macrophages Through Interference With Activator Protein-1 Signaling Pathways. Circulation Research, 2005, 96, e59-67.	4.5	91
52	Transcriptional Repression of ATP-Binding Cassette Transporter A1 Gene in Macrophages. Circulation Research, 2005, 97, e88-96.	4.5	34
53	Liver X Receptors: Potential Novel Targets in Cardiovascular Diseases. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 533-540.	2.0	20
54	Liver X Receptor Agonists Suppress Vascular Smooth Muscle Cell Proliferation and Inhibit Neointima Formation in Balloon-Injured Rat Carotid Arteries. Circulation Research, 2004, 95, e110-23.	4.5	85

Dennis Bruemmer

#	Article	IF	CITATIONS
55	Peroxisome Proliferator-Activated Receptor Î ³ : Implications for Cardiovascular Disease. Hypertension, 2004, 43, 297-305.	2.7	134
56	C-Reactive Protein Induces Apoptosis in Human Coronary Vascular Smooth Muscle Cells. Circulation, 2004, 110, 579-587.	1.6	128
57	Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells. Oncogene, 2004, 23, 4614-4623.	5.9	82
58	Egr-1 is a Major Vascular Pathogenic Transcription Factor in Atherosclerosis and Restenosis. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 249-254.	5.7	64
59	Will the potential of peroxisome proliferator-activated receptor agonists be realized in the clinical setting?. Clinical Cardiology, 2004, 27, 3-10.	1.8	9
60	Osteopontin modulates angiotensin II- induced fibrosis in the intact murine heart. Journal of the American College of Cardiology, 2004, 43, 1698-1705.	2.8	124
61	PPARÎ ³ signalling and vascular cells in 2003. International Congress Series, 2004, 1262, 143-146.	0.2	Ο
62	Rapamycin inhibits E2F-dependent expression of minichromosome maintenance proteins in vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 2003, 303, 251-258.	2.1	21
63	p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells. Biochemical and Biophysical Research Communications, 2003, 305, 552-556.	2.1	16
64	PGE2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochemical and Biophysical Research Communications, 2003, 306, 887-897.	2.1	112
65	Expression of minichromosome maintenance proteins in vascular smooth muscle cells is ERK/MAPK dependent. Experimental Cell Research, 2003, 290, 28-37.	2.6	19
66	Regulation of the Growth Arrest and DNA Damage-Inducible Gene 45 (GADD45) by Peroxisome Proliferator-Activated Receptor γ in Vascular Smooth Muscle Cells. Circulation Research, 2003, 93, e38-47.	4.5	86
67	Inhibitory Activity of Clinical Thiazolidinedione Peroxisome Proliferator Activating Receptor-Î ³ Ligands Toward Internal Mammary Artery, Radial Artery, and Saphenous Vein Smooth Muscle Cell Proliferation. Circulation, 2003, 107, 2548-2550.	1.6	94
68	Peroxisome Proliferator-Activated Receptor Î ³ Inhibits Expression of Minichromosome Maintenance Proteins in Vascular Smooth Muscle Cells. Molecular Endocrinology, 2003, 17, 1005-1018.	3.7	32
69	Angiotensin II–accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. Journal of Clinical Investigation, 2003, 112, 1318-1331.	8.2	241
70	PPARα Inhibits TGF-β–Induced β 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4. Circulation Research, 2002, 91, e35-44.	4.5	62
71	TGF-β1 induces peroxisome proliferator-activated receptor γ1 and γ2 expression in human THP-1 monocytes. Biochemical and Biophysical Research Communications, 2002, 297, 794-799.	2.1	22
72	Increased expression of renal neutral endopeptidase in severe heart failure. Life Sciences, 2002, 71, 2701-2712.	4.3	65

#	Article	IF	CITATIONS
73	TNFα Inhibits Insulin's Antiapoptotic Signaling in Vascular Smooth Muscle Cells. Biochemical and Biophysical Research Communications, 2001, 287, 662-670.	2.1	22
74	Expression of CD40 in vascular smooth muscle cells and macrophages is associated with early development of human atherosclerotic lesions. American Journal of Cardiology, 2001, 87, 21-27.	1.6	53